Neuphoria Therapeutics Inc.
NEUP
$4.66
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -100.08% | 2,161.46% | -- | -- | 211,558.11% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -100.08% | 2,161.46% | -- | -- | 35,535.97% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -100.08% | 2,161.46% | 869.05% | 405.47% | 1,087.25% |
| SG&A Expenses | -4.13% | -4.91% | 2.97% | -8.09% | -11.98% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -9.20% | 8.71% | 16.77% | -7.41% | -10.98% |
| Operating Income | -3,015.55% | 87.45% | 81.67% | 95.34% | 97.41% |
| Income Before Tax | -418.40% | 27.18% | 10.60% | 94.62% | 130.74% |
| Income Tax Expenses | -57.27% | -201.81% | -100.87% | -436.54% | -167.46% |
| Earnings from Continuing Operations | -399.14% | 31.04% | 12.50% | 97.61% | 132.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -399.14% | 31.04% | 12.50% | 97.61% | 132.19% |
| EBIT | -3,015.55% | 87.45% | 81.67% | 95.34% | 97.41% |
| EBITDA | -7,383.51% | 91.53% | 85.22% | 99.03% | 101.10% |
| EPS Basic | -750.91% | 73.61% | 68.92% | 100.23% | 116.52% |
| Normalized Basic EPS | -451.83% | 79.98% | 72.82% | 97.34% | 80.54% |
| EPS Diluted | -1,366.98% | 61.52% | 64.29% | 95.35% | 109.64% |
| Normalized Diluted EPS | -451.83% | 79.98% | 72.82% | 97.34% | 80.54% |
| Average Basic Shares Outstanding | 161.21% | 123.34% | 88.88% | -99.57% | -99.83% |
| Average Diluted Shares Outstanding | 161.21% | 123.34% | 88.88% | -99.57% | -99.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |